BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$66.60 USD
+0.71 (1.08%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $66.63 +0.03 (0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 36% (89 out of 250)Zacks Sector Rank
Top 19% (3 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.58 | 1.38 | 9.99 |
Current Quarter Estimate | 0.74 | 1.62 | 63.00 |
Year Ago Quarter Estimate | 0.49 | -4.98 | 52.25 |
Next Quarter Estimate | 0.83 | 3.45 | 66.00 |
Next Year Estimate | 3.97 | 21.80 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 57.21 | 17.50 | 15.67 |
Next Year | 21.41 | 9.20 | 11.34 |
Last 5 Years | NA | 4.00 | 8.10 |
Next 5 Years | 41.00 | 21.30 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 21.69 | -7.23 |
Price/Book (MRQ) | 2.34 | 1.97 |
Price/Cash Flow (MRFY) | 37.23 | 14.45 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | 11.71% | -6.09% |
Return on Equity (TTM) | 8.53% | -35.66% |
Debt to Equity (MRQ) | 0.11 | 18.11 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.